Bristol-Myers Squibb Company – NYSE:BMY
Bristol-Myers Squibb Company stock price today
$48.34
-9.33
-16.19%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
Bristol-Myers Squibb Company stock price monthly change
+42.56%
month
Bristol-Myers Squibb Company stock price quarterly change
+42.56%
quarter
Bristol-Myers Squibb Company stock price yearly change
+12.63%
year
Bristol-Myers Squibb Company key metrics
Market Cap | 115.56B |
Enterprise value | 160.49B |
P/E | -16.11 |
EV/Sales | 3.38 |
EV/EBITDA | 31.73 |
Price/Sales | 2.46 |
Price/Book | 6.82 |
PEG ratio | -3.66 |
EPS | -3.09 |
Revenue | 45.53B |
EBITDA | 17.43B |
Income | -6.14B |
Revenue Q/Q | 4.65% |
Revenue Y/Y | -0.68% |
Profit margin | -15.3% |
Oper. margin | 21.74% |
Gross margin | 70.41% |
EBIT margin | 21.74% |
EBITDA margin | 38.29% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeBristol-Myers Squibb Company stock price history
Bristol-Myers Squibb Company stock forecast
Bristol-Myers Squibb Company financial statements
Average Price Target
$55.33
Potential upside: 14.46%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 11.22B | 2.07B | 18.47% |
|---|---|---|---|
| Sep 2023 | 10.96B | 1.92B | 17.58% |
| Dec 2023 | 11.47B | 1.76B | 15.35% |
| Mar 2024 | 11.86B | -11.91B | -100.39% |
Paying a dividend while loss making.
4.16%
Yield TTM
| Payout ratio | -66.2% |
|---|
| 2019 | 2.45% |
|---|---|
| 2020 | 2.91% |
| 2021 | 3.17% |
| 2022 | 3.02% |
| 2023 | 4.47% |
| Jun 2023 | 93489000000 | 61.45B | 65.74% |
|---|---|---|---|
| Sep 2023 | 91263000000 | 62.20B | 68.16% |
| Dec 2023 | 95159000000 | 65.67B | 69.02% |
| Mar 2024 | 99031000000 | 82.48B | 83.29% |
| Jun 2023 | 1.88B | -329M | -2.17B |
|---|---|---|---|
| Sep 2023 | 4.75B | -410M | -5.16B |
| Dec 2023 | 4.25B | -1.34B | 967M |
| Mar 2024 | 2.83B | -19.61B | 14.64B |
Bristol-Myers Squibb Company alternative data
Bristol-Myers Squibb Company Social Media Accounts
What are followers?
+0.18%
month
| Sep 2023 | 138818 |
|---|
+45.28%
month
| May 2025 | 21420 |
|---|
Areas of Focus
| 4 Aug 2024 | 48 | 14 | 15 | 53 | 0 |
|---|---|---|---|---|---|
| 11 Aug 2024 | 54 | 14 | 16 | 53 | 0 |
| 18 Aug 2024 | 61 | 14 | 16 | 51 | 0 |
| 25 Aug 2024 | 69 | 14 | 16 | 55 | 0 |
| 1 Sep 2024 | 72 | 14 | 15 | 53 | 0 |
| 8 Sep 2024 | 78 | 15 | 15 | 57 | 0 |
| 15 Sep 2024 | 85 | 15 | 16 | 57 | 0 |
| 22 Sep 2024 | 79 | 15 | 15 | 56 | 0 |
| 29 Sep 2024 | 86 | 15 | 16 | 55 | 0 |
| 6 Oct 2024 | 76 | 14 | 15 | 53 | 0 |
| 13 Oct 2024 | 80 | 13 | 15 | 51 | 0 |
| 20 Oct 2024 | 72 | 13 | 14 | 50 | 0 |
| 27 Oct 2024 | 66 | 12 | 13 | 48 | 0 |
| 3 Nov 2024 | 74 | 14 | 14 | 51 | 0 |
| 10 Nov 2024 | 67 | 13 | 15 | 50 | 0 |
| 17 Nov 2024 | 60 | 12 | 12 | 42 | 0 |
| 24 Nov 2024 | 65 | 13 | 15 | 53 | 0 |
| 1 Dec 2024 | 64 | 14 | 15 | 51 | 0 |
| 8 Dec 2024 | 56 | 12 | 14 | 52 | 0 |
| 15 Dec 2024 | 34 | 10 | 11 | 36 | 0 |
Bristol Myers
| 21 May 2023 | 32 | 26 |
|---|---|---|
| 28 May 2023 | 29 | 23 |
| 4 Jun 2023 | 31 | 26 |
| 11 Jun 2023 | 31 | 25 |
| 18 Jun 2023 | 30 | 25 |
| 25 Jun 2023 | 31 | 27 |
| 2 Jul 2023 | 30 | 25 |
| 9 Jul 2023 | 27 | 23 |
| 16 Jul 2023 | 38 | 31 |
| 23 Jul 2023 | 31 | 25 |
| 30 Jul 2023 | 26 | 22 |
| 6 Aug 2023 | 29 | 25 |
| 13 Aug 2023 | 31 | 25 |
| 20 Aug 2023 | 33 | 26 |
| 27 Aug 2023 | 44 | 36 |
| 3 Sep 2023 | 30 | 24 |
| 10 Sep 2023 | 32 | 26 |
| 17 Sep 2023 | 32 | 27 |
| 24 Sep 2023 | 36 | 27 |
| 1 Oct 2023 | 22 | 17 |
Bristol Myers Products
| 12 Feb 2023 | 1 | 3 | 5 | 67 | 4 |
|---|---|---|---|---|---|
| 19 Feb 2023 | 2 | 4 | 4 | 64 | 5 |
| 26 Feb 2023 | 2 | 3 | 4 | 64 | 4 |
| 5 Mar 2023 | 2 | 4 | 5 | 69 | 5 |
| 12 Mar 2023 | 1 | 3 | 5 | 63 | 6 |
| 19 Mar 2023 | 2 | 3 | 6 | 69 | 5 |
| 26 Mar 2023 | 1 | 4 | 7 | 66 | 5 |
| 2 Apr 2023 | 1 | 4 | 6 | 64 | 11 |
| 9 Apr 2023 | 1 | 4 | 5 | 65 | 9 |
| 16 Apr 2023 | 1 | 3 | 6 | 67 | 5 |
| 23 Apr 2023 | 1 | 4 | 5 | 67 | 5 |
| 30 Apr 2023 | 2 | 3 | 5 | 68 | 6 |
| 7 May 2023 | 1 | 3 | 5 | 61 | 4 |
| 14 May 2023 | 2 | 3 | 6 | 68 | 6 |
| 21 May 2023 | 1 | 4 | 4 | 69 | 6 |
| 28 May 2023 | 1 | 3 | 5 | 64 | 5 |
| 4 Jun 2023 | 1 | 4 | 4 | 70 | 7 |
| 11 Jun 2023 | 1 | 3 | 4 | 69 | 6 |
| 18 Jun 2023 | 1 | 3 | 5 | 72 | 6 |
| 25 Jun 2023 | 2 | 3 | 3 | 59 | 4 |
Numbers represent search interest relative to the highest point on the chart for the given region and time.
A value of 100 is the peak popularity for the term.
A value of 50 means that the term is half as popular.
A score of 0 means there was not enough data for this term.
What is job openings count?
| Sep 2023 | 1,088 |
|---|---|
| Oct 2023 | 900 |
| Jan 2025 | 628 |
| Feb 2025 | 649 |
| May 2025 | 622 |
| Jul 2025 | 866 |
| Aug 2025 | 731 |
| Sep 2023 | 34,300 |
|---|---|
| Oct 2023 | 34,300 |
| Nov 2023 | 34,300 |
| Dec 2023 | 34,300 |
| Jan 2024 | 34,300 |
| Feb 2024 | 34,300 |
| Apr 2024 | 34,100 |
| May 2024 | 34,100 |
| Jun 2024 | 34,100 |
| Jul 2024 | 34,100 |
Bristol-Myers Squibb Company other data
71.26%
+0.18%
of BMY is owned by hedge funds
2.41K
+35
1.59B
+5.38M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| May 2023 | 0 | 50385 |
| Aug 2023 | 0 | 18718 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | SHANAHAN KARIN officer: EVP, Glob. Prod. Dev. .. | Restricted Stock Units | 3,306 | N/A | N/A | ||
Option | SHANAHAN KARIN officer: EVP, Glob. Prod. Dev. .. | Common Stock, $0.10 par value | 3,306 | N/A | N/A | ||
Option | LENKOWSKY ADAM officer: EVP, Chief Commercial .. | Common Stock, $0.10 par value | 11,416 | N/A | N/A | ||
Option | LENKOWSKY ADAM officer: EVP, Chief Commercial .. | Common Stock, $0.10 par value | 1,902 | N/A | N/A | ||
Option | LENKOWSKY ADAM officer: EVP, Chief Commercial .. | Common Stock, $0.10 par value | 1,698 | N/A | N/A | ||
Option | LENKOWSKY ADAM officer: EVP, Chief Commercial .. | Market Share Units | 1,902 | N/A | N/A | ||
Option | LENKOWSKY ADAM officer: EVP, Chief Commercial .. | Performance Shares | 11,416 | N/A | N/A | ||
Option | LENKOWSKY ADAM officer: EVP, Chief Commercial .. | Market Share Units | 1,698 | N/A | N/A | ||
Option | LEUNG SANDRA officer: EVP, Gen.. | Common Stock, $0.10 par value | 35,139 | N/A | N/A | ||
Option | LEUNG SANDRA officer: EVP, Gen.. | Common Stock, $0.10 par value | 5,856 | N/A | N/A |
| Patent |
|---|
Grant Utility: Fibronectin based scaffold proteins Filling date: 10 Jan 2020 Issue date: 20 Sep 2022 |
Grant Filling date: 11 Jan 2019 Issue date: 20 Sep 2022 |
Grant Filling date: 3 Jan 2019 Issue date: 20 Sep 2022 |
Grant Filling date: 18 Dec 2018 Issue date: 20 Sep 2022 |
Grant Filling date: 3 Aug 2018 Issue date: 20 Sep 2022 |
Grant Filling date: 11 Jul 2018 Issue date: 20 Sep 2022 |
Grant Filling date: 29 Oct 2018 Issue date: 13 Sep 2022 |
Application Filling date: 22 Mar 2022 Issue date: 8 Sep 2022 |
Application Filling date: 5 Aug 2020 Issue date: 8 Sep 2022 |
Grant Filling date: 21 Jan 2020 Issue date: 6 Sep 2022 |
| Quarter | Transcript |
|---|---|
| Q1 2024 25 Apr 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 2 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 26 Oct 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 27 Jul 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Dr. Giovanni Caforio (1965) Chairman & Chief Executive Officer | $6,690,000 |
| Mr. David V. Elkins (1968) Executive Vice President & Chief Financial Officer | $3,240,000 |
Mr. Rupert Vessey M.A. (1965) Executive Vice President and Pres of Research & Early Devel. | $3,240,000 |
| Ms. Sandra Leung Esq. (1961) Executive Vice President & Gen. Counsel | $3,030,000 |
| Dr. Christopher S. Boerner (1971) Executive Vice President & Chief Commercialization Officer | $2,780,000 |
Why Johnson & Johnson Stock Still Has Room To Run
Bristol-Myers Squibb: Buy The Weakness
Lyell: 'Hold' Rating Based On Phase 3 LYL314 LBCL Treatment Program Advancement
Undercovered Dozen: Morgan Stanley, Arista Networks, Global Ship Lease And More
Bristol Myers Squibb: Hidden Facts Blur The Strength Of The Company
Merck & Co.: A Pharma Titan At A Discount
Bristol-Myers Squibb: Strong Launch Portfolio Amid Market Reset
Merck: Don't Let Today's Bargain Opportunity Pass You By
Exelixis: Zanzalintinib MOA Overcomes Competing CRC Regorafenib Treatment
-
What's the price of Bristol-Myers Squibb Company stock today?
One share of Bristol-Myers Squibb Company stock can currently be purchased for approximately $48.34.
-
When is Bristol-Myers Squibb Company's next earnings date?
Unfortunately, Bristol-Myers Squibb Company's (BMY) next earnings date is currently unknown.
-
Does Bristol-Myers Squibb Company pay dividends?
Yes, Bristol-Myers Squibb Company pays dividends and its trailing 12-month yield is 4.16% with -66% payout ratio.It means that the company is paying a dividend while loss making. The last Bristol-Myers Squibb Company stock dividend of $0.54 was paid on 1 Feb 2022.
-
How much money does Bristol-Myers Squibb Company make?
Bristol-Myers Squibb Company has a market capitalization of 115.56B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 2.5% to 45.01B US dollars.
-
What is Bristol-Myers Squibb Company's stock symbol?
Bristol-Myers Squibb Company is traded on the NYSE under the ticker symbol "BMY".
-
What is Bristol-Myers Squibb Company's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - General industry.
-
How do i buy shares of Bristol-Myers Squibb Company?
Shares of Bristol-Myers Squibb Company can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Bristol-Myers Squibb Company's key executives?
Bristol-Myers Squibb Company's management team includes the following people:
- Dr. Giovanni Caforio Chairman & Chief Executive Officer(age: 60, pay: $6,690,000)
- Mr. David V. Elkins Executive Vice President & Chief Financial Officer(age: 57, pay: $3,240,000)
- Mr. Rupert Vessey M.A. Executive Vice President and Pres of Research & Early Devel.(age: 60, pay: $3,240,000)
- Ms. Sandra Leung Esq. Executive Vice President & Gen. Counsel(age: 64, pay: $3,030,000)
- Dr. Christopher S. Boerner Executive Vice President & Chief Commercialization Officer(age: 54, pay: $2,780,000)
-
How many employees does Bristol-Myers Squibb Company have?
As Jul 2024, Bristol-Myers Squibb Company employs 34,100 workers.
-
When Bristol-Myers Squibb Company went public?
Bristol-Myers Squibb Company is publicly traded company for more then 53 years since IPO on 1 Jun 1972.
-
What is Bristol-Myers Squibb Company's official website?
The official website for Bristol-Myers Squibb Company is bms.com.
-
Where are Bristol-Myers Squibb Company's headquarters?
Bristol-Myers Squibb Company is headquartered at 430 East 29th Street, New York, NY.
-
How can i contact Bristol-Myers Squibb Company?
Bristol-Myers Squibb Company's mailing address is 430 East 29th Street, New York, NY and company can be reached via phone at +212 5464000.
-
What is Bristol-Myers Squibb Company stock forecast & price target?
Based on 2 Wall Street analysts` predicted price targets for Bristol-Myers Squibb Company in the last 12 months, the avarage price target is $55.33. The average price target represents a 14.46% change from the last price of $48.34.
Bristol-Myers Squibb Company company profile:
Bristol-Myers Squibb Company
bms.comExchange:
NYSE
Full time employees:
34,100
Industry:
Drug Manufacturers - General
Sector:
Healthcare
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
430 East 29th Street
New York, NY 10016
New York, NY 10016
CIK: 0000014272
ISIN: US1101221083
CUSIP: 110122108
